Insulin Glargine Biosimilar – Anti-INS – Research Grade from ProteoGenix; catalogue PX-TA2298; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Insulin Glargine Biosimilar, also known as Anti-INS, is a novel antibody that has shown great potential in the treatment of diabetes. It is a biosimilar of insulin glargine, a long-acting insulin analog commonly used in the management of diabetes mellitus. In this article, we will explore the structure, activity, and application of Insulin Glargine Biosimilar as a therapeutic target for diabetes.
Insulin Glargine Biosimilar is a monoclonal antibody that specifically targets insulin. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The heavy chains consist of constant and variable regions, while the light chains have only variable regions. The variable regions of the antibody are responsible for binding to insulin and inhibiting its activity.
Insulin Glargine Biosimilar works by binding to insulin and preventing its interaction with its receptor on the surface of cells. This leads to a decrease in the uptake of glucose by cells, thereby reducing the levels of glucose in the blood. As a result, it helps to control blood sugar levels in individuals with diabetes.
Insulin Glargine Biosimilar has been shown to have a high affinity for insulin and a long half-life, making it a potent inhibitor of insulin activity. In addition, it has been found to have a low immunogenicity, meaning that it is unlikely to cause an immune response in the body. This makes it a safe and effective option for long-term use in the treatment of diabetes.
Insulin Glargine Biosimilar has a wide range of potential applications in the treatment of diabetes. It can be used as a standalone therapy or in combination with other diabetes medications, such as oral hypoglycemic agents or short-acting insulin. It is also being studied for its potential use in the prevention of type 1 diabetes in high-risk individuals.
Moreover, Insulin Glargine Biosimilar has shown promising results in clinical trials for its use in insulin pump therapy, a method of delivering insulin continuously throughout the day. This could greatly improve the management of diabetes and provide better glycemic control for patients.
In summary, Insulin Glargine Biosimilar is a promising antibody for the treatment of diabetes. Its unique structure, high affinity for insulin, and low immunogenicity make it a valuable therapeutic target. With ongoing research and clinical trials, it has the potential to revolutionize the management of diabetes and improve the quality of life for patients.
Insulin Glargine Biosimilar, Anti-INS, antibody, therapeutic target, diabetes, structure, activity, application.
ProteoGenix catalogue number PX-TA2298. For research use only.
Target: Insulin Glargine Biosimilar – Anti-INS – Research Grade; Host: Human; Clonality: Polyclonal Antibody.
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
